CellType, a Yale University spinout, has joined Y Combinator’s W26 batch with a platform that combines foundation models of human biology with AI agents designed …
Read More
The US Food and Drug Administration has formally shifted its evidentiary baseline for new drug applications, stating that one well-controlled clinical trial will now serve …
Read More
Deep Origin, in partnership with Arctoris, has been selected for the Advanced Research + Invention Agency’s AI Scientist program (ARIA), one of the UK’s most …
Read More
Korsana Biosciences has launched with $175 million in combined seed and Series A financing to develop brain-penetrant antibody therapies for neurodegenerative diseases. The company’s main …
Read More
Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase …
Read More
Scribe Therapeutics reported a second milestone, achieved with the help of Scribe’s proprietary X-Editor (XE) platform, in its multi-program collaboration with Eli Lilly focused on …
Read More
